Related Experiment Video
Updated: Nov 22, 2025

Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty
Published on: January 28, 2020
Update on the Inflammatory Hypothesis of Coronary Artery Disease
1Department of Internal Medicine, George Washington University Hospital, Washington, DC, USA. jboland@gwu.edu.
Insights
Inflammation plays a key role in coronary artery disease (CAD) progression. Recent trials highlight cost-effective anti-inflammatory therapies as the future of preventative CAD treatment.
Area of Science:
- Cardiovascular Medicine
- Immunology
Background:
- Coronary artery disease (CAD) pathogenesis involves inflammation alongside cholesterol imbalance.
- Emerging evidence supports the inflammatory hypothesis of CAD.
Purpose of the Study:
- To review recent clinical trials supporting the inflammatory hypothesis of CAD.
- To discuss the future of preventative CAD treatment focusing on cost-effective anti-inflammatory therapies.
Main Methods:
- Review of key clinical trials including CANTOS, CIRT, COLCOT, and LoDoCo2.
- Analysis of anti-inflammatory and anti-cytokine agents in CAD prevention.
Main Results:
- Canakinumab (anti-interleukin-1β) reduced cardiovascular events but is not cost-effective.
- Colchicine trials (COLCOT, LoDoCo2) and CIRT provide further support for inflammation's role.
- Cost-effective anti-inflammatory treatments are needed for preventative CAD therapy.
Conclusions:
- Inflammation is a critical driver of CAD progression.
- Targeting inflammation with cost-effective therapies represents a promising future for CAD prevention.
- Further research into specific anti-inflammatory targets is warranted.
Purpose Of Review:
The pathogenesis and progression of coronary artery disease (CAD) is now known to be largely driven by inflammation on top of the well-accepted role for the disequilibrium between cholesterol deposition and removal from the arterial wall. Recent clinical trials have supported the inflammatory hypothesis of CAD and will be discussed in this review.
Recent Findings:
The clinical trial Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS) found that treatment with canakinumab, an anti-interleukin-1β agent, resulted in a reduction in non-fatal myocardial infarction, non-fatal stroke, or death. This provided evidence for the inflammatory hypothesis of CAD. However, canakinumab is not cost-effective for widespread therapy and more cost-effective treatments are warranted. The Cardiovascular Inflammation Reduction Trial (CIRT), Colchicine Cardiovascular Outcomes Trial (COLCOT), and Low-Dose Colchicine 2 (LoDoCo2) are recent clinical trials that increased the understanding of the inflammatory hypothesis of CAD. Cost-effective therapies targeting inflammation are the future of preventative CAD treatment. Additional clinical trials with anti-inflammatory and anti-cytokine agents would help delineate the most beneficial target for CAD prevention.
More Related Videos
Related Concept Videos
Coronary Artery Disease II: Pathophysiology
Coronary Artery Disease I: Introduction
Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations
Myocarditis I: Introduction
Inflammation
Atherosclerosis I: Introduction

